4C Biomed
Unlocking the Promise of Immune Checkpoint Inhibitors
Company Overview
Snapshot
Founded in February 2016 by Eyal Greenberg and Gal Markel, 4C Biomed operates with 1–10 employees. The company has secured funding across one round from one investor, Israel Biotech Fund. A key development for 4C Biomed is its lead drug, an IND-ready asset, which is slated to enter clinical Phase I in 2026.
Business overview
4C Biomed is a Health Tech & Life Sciences company focused on the research and development of immuno-oncology therapies. The company leverages a sensitive, immunological-based screening platform to identify novel immuno-oncology targets and accelerate drug discovery. Its core technology involves unique autologous cell systems, utilizing cancer and immune cells from the same patient to drive therapeutic development. 4C Biomed operates within the Pharmaceuticals and Life Sciences markets, specifically targeting Drugs Discovery & Development.
Log in to access full profile ›Company Intelligence Q&A
- When was 4C Biomed founded and by whom?
- 4C Biomed was founded in February 2016 by co-founders Eyal Greenberg and Gal Markel.
- What is the primary focus of 4C Biomed's research and development?
- 4C Biomed focuses on the research and development of immuno-oncology therapies, utilizing unique autologous cell systems and an immunological-based screening platform to identify novel targets.
- What is the status of 4C Biomed's lead drug candidate?
- 4C Biomed's lead drug is an IND-ready asset and is planned to enter clinical Phase I in 2026.
- What is 4C Biomed's primary sector and product stage?
- 4C Biomed operates in the Health Tech & Life Sciences sector, with its products currently in the R&D stage.